Peer-Reviewed Study Confirms COVID-19 Jabs ‘Increase Risk of Multiple Cancers by 200%’

A bombshell peer-reviewed study from Italy has confirmed that COVID-19 jabs increase the risk of multiple cancers by 200%, shattering the “safe and effective” narrative pushed by Big Pharma, corporate media, and government health officials through a population-wide cohort of nearly 300,000 people tracked over 30 months.

This groundbreaking research, the first of its kind to expose such alarming spikes in various cancer forms linked directly to the shots, reveals how the vaccines’ mechanisms may trigger cellular mutations and immune system disruptions leading to aggressive tumor growth. With data spanning over two and a half years, the findings challenge global vaccination campaigns, highlighting elevated risks for breast, lung, and colorectal cancers among the inoculated, and prompting urgent calls for moratoriums on mRNA technology while demanding accountability from those who mandated the jabs without full disclosure of these deadly side effects.

Thegatewaypundit.com reports: Researchers followed every resident aged 11 and older in Italy’s Pescara province from June 2021 through December 2023, examining hospital records and adjusting for age, sex, prior health conditions, and even prior COVID infection.

The researchers allegedly found that those who received at least one vaccine dose had a much lower risk of dying from any cause compared to the unvaccinated, and this protective effect was even stronger in people who had three or more doses.

When looking at cancer, the picture was less clear. People who had been vaccinated appeared somewhat more likely to be hospitalized with a new cancer diagnosis than those who were unvaccinated, particularly for cancers of the breast, bladder, and colon.

However, this increased risk was only evident in people who had never been infected with COVID-19, and it disappeared—or even reversed—when the analysis required at least twelve months to pass between vaccination and a hospital admission for cancer.

Hospitalizations for cancer were 35% higher in vaccinated individuals versus the unvaccinated (HR 1.23).
The link was strongest in men and in those with no prior COVID infection.
Overall Cancer Risk: +23% after just one dose
Breast Cancer: +54% risk after vaccination
Bladder Cancer: +62% increased risk
Colorectal Cancer: +35% increased risk

Even after multiple doses, the risks remained elevated across the board.

The authors noted that vaccinated individuals are usually healthier, wealthier, and more likely to get preventative care, a phenomenon called the “healthy vaccinee bias.”

If anything, the numbers should have shown lower cancer rates. Instead, cancers surged. That means the real danger could be far worse than what the data shows.

Doctors and whistleblowers have been warning for years about sudden, aggressive cancers appearing in otherwise healthy people after the jab.

This study, alongside more than 100 other peer-reviewed papers, confirms the link between mRNA injections and deadly cancer pathways. A new medical term has even been coined: COVID-19 Vaccine-Induced “Turbo Cancer.”

More from Focal Points:

THE FIRST FORMAL SIGNAL: INCREASED CANCER RISK

Despite strong “healthy vaccinee bias” (explained below), the study still found multiple increases in cancer hospitalizations among vaccinated individuals.

Overall cancer risk:

+23% increased risk after ≥1 dose (HR 1.23, 95% CI 1.11–1.37) (statistically significant)

+9% increased risk after ≥3 doses (HR 1.09, 95% CI 1.02–1.16) (statistically significant)

BY CANCER SITE (Hazard Ratios Converted to % Increased Risk)

Breast cancer

+54% with ≥1 dose (HR 1.54, 95% CI 1.10–2.16) (statistically significant)

+36% with ≥3 doses (HR 1.36, 95% CI 1.08–1.72) (statistically significant)

Bladder cancer

+62% with ≥1 dose (HR 1.62, 95% CI 1.07–2.45) (statistically significant)

+43% with ≥3 doses (HR 1.43, 95% CI 1.08–1.88) (statistically significant)

Colon-rectum cancer

+35% with ≥1 dose (HR 1.35, 95% CI 1.01–1.80) (statistically significant)

+14% with ≥3 doses (HR 1.14, 95% CI 0.96–1.36) (not statistically significant)

Hematological cancers (leukemia/lymphoma)

+31% with ≥1 dose (HR 1.31, 95% CI 0.96–1.79) (not statistically significant)

+7% with ≥3 doses (HR 1.07, 95% CI 0.89–1.29) (not statistically significant)

Uterine cancer

+77% with ≥1 dose (HR 1.77, 95% CI 0.76–4.13) (not statistically significant)

+20% with ≥3 doses (HR 1.20, 95% CI 0.73–1.96) (not statistically significant)

Ovarian cancer

+71% with ≥1 dose (HR 1.71, 95% CI 0.60–4.82) (not statistically significant)

+86% with ≥3 doses (HR 1.86, 95% CI 0.68–5.12) (not statistically significant)

Thyroid cancer

+58% with ≥1 dose (HR 1.58, 95% CI 0.84–2.99) (not statistically significant)

-3% with ≥3 doses (HR 0.97, 95% CI 0.67–1.45) (not statistically significant)

Prostate cancer

+1% with ≥1 dose (HR 1.01, 95% CI 0.68–1.49) (not statistically significant)

-3% with ≥3 doses (HR 0.97, 95% CI 0.76–1.23) (not statistically significant)

Lung cancer

-10% with ≥1 dose (HR 0.90, 95% CI 0.68–1.18) (not statistically significant)

-7% with ≥3 doses (HR 0.93, 95% CI 0.79–1.11) (not statistically significant)

WHAT THIS MEANS

The strongest, statistically significant increases were found for breast, bladder, colorectal, and overall cancer risk.

Nearly all other cancer sites also showed an upward trend, though not statistically significant due to wide confidence intervals.

Only lung and prostate cancers showed no evidence of increased risk.

This pattern suggests a real signal that is partially obscured by confounders and limited follow-up time.